x

Posted 10 January, 2024

CuraScientific Corp. appointed Samuel Berry as new CEO

OTC:CSTF appointed new Chief Executive Officer Samuel Berry in a 8-K filed on 10 January, 2024.


  On December 29, 2023, the Board of Directors of the Company appointed Samuel Berry to serve as the Interim Chairman of the Board of the Company, Chief Executive Officer, President and Secretary.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of CuraScientific Corp.
None • None
CuraScientific Corp. is a bioscience company, which engages in the manufacture of commercial chemical products with applications in commercial sterilization for agriculture, warehousing, hospitality, and medical facilities. The company is headquartered in Coachella, CA.
Market Cap
$377K
View Company Details
CuraScientific Corp. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Resignations of Directors and Officers


On December 29, 2023 William Reed resigned as Chairman, CEO, Secretary and Treasurer from Curascientific Corporation, (the "Company"). As a part of this dismissal, Mr. Reed will cancel and return to treasury all Preferred Series B Shares.


Appointment of Samuel Berry


On December 29, 2023, the Board of Directors of the Company appointed Samuel Berry to serve as the Interim Chairman of the Board of the Company, Chief Executive Officer, President and Secretary.


Samuel Berry, age 46, is a graduate from Keene State College in New Hampshire with a Bachelor of Science, and a graduate of Florida International University with a Master of Science. Mr. Berry has 10 years' experience with the operations of public companies; with over 20 years of business experience in management.


In connection with this appointment as Chairman and Chief Executive Officer, Mr. Berry entered into an employment agreement with the Company with a one- year term, pursuant to which Mr. Berry will receive $50,000 in Preferred Series A Stock and 2,500 Preferred Series B Shares.


Other than as set forth above, there are no arrangements or understandings with Mr. Berry pursuant to which he was appointed as an officer director of the Company, and there are no related party transactions between the Company and Mr. Berry that are subject to disclosure under Item 404(a) of Regulation S-K.